Ebola virus disease has features of hemophagocytic lymphohistiocytosis syndrome

Frontiers in Medicine

Volumn 2, Issue FEB, 2015, Pages

  van der Ven, Andre J A M ^a   Netea, Mihai G ^a   van der Meer, Jos W M ^a   de Mast, Quirijn ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Anakinra; Cytokines; Ebola virus; Ferritins; Macrophage activation

Indexed keywords

EID: 84940469023     PISSN: None     EISSN: 2296858X     Source Type: Journal    
DOI: 10.3389/fmed.2015.00004     Document Type: Note

References (20)

1. Feldmann H, Geisbert TW. Ebola haemorrhagic fever. Lancet (2011) 377(9768):849-62. doi:10.1016/S0140-6736(10)60667-8
2. Geisbert TW, Young HA, Jahrling PB, Davis KJ, Larsen T, Kagan E, et al. Pathogenesis of Ebola hemorrhagic fever in primate models: evidence that hemorrhage is not a direct effect of virus-induced cytolysis of endothelial cells. Am J Pathol (2003) 163(6):2371-82. doi:10.1016/S0002-9440(10)63592-4
3. Sanchez A, Lukwiya M, Bausch D, Mahanty S, Sanchez AJ, Wagoner KD, et al. Analysis of human peripheral blood samples from fatal and nonfatal cases of Ebola (Sudan) hemorrhagic fever: cellular responses, virus load, and nitric oxide levels. J Virol (2004) 78(19):10370-7. doi:10.1128/JVI.78.19.10370-10377.2004
4. Rollin PE, Bausch DG, Sanchez A. Blood chemistry measurements and d-Dimer levels associated with fatal and nonfatal outcomes in humans infected with Sudan Ebola virus. J Infect Dis (2007) 196(Suppl 2):S364-71. doi:10.1086/520613
5. Martines RB, Ng DL, Greer PW, Rollin PE, Zaki SR. Tissue and cellular tropism, pathology and pathogenesis of Ebola and Marburg viruses. J Pathol (2014) 235(2):153-74. doi:10.1002/path.4456
6. McElroy AK, Erickson BR, Flietstra TD, Rollin PE, Nichol ST, Towner JS, et al. Ebola hemorrhagic fever: novel biomarker correlates of clinical outcome. J Infect Dis (2014) 210(4):558-66. doi:10.1093/infdis/jiu088
7. Ebihara H, Rockx B, Marzi A, Feldmann F, Haddock E, Brining D, et al. Host response dynamics following lethal infection of rhesus macaques with Zaire Ebola virus. J Infect Dis (2011) 204(Suppl 3):S991-9. doi:10.1093/infdis/jir336
8. Rosado FG, Kim AS. Hemophagocytic lymphohistiocytosis: an update on diagnosis and pathogenesis. Am J Clin Pathol (2013) 139(6):713-27. doi:10.1309/AJCP4ZDKJ4ICOUAT
9. Terrell CE, Jordan MB. Perforin deficiency impairs a critical immunoregulatory loop involving murine CD8(+) T cells and dendritic cells. Blood (2013) 121(26):5184-91. doi:10.1182/blood-2013-04-495309
10. Baize S, Leroy EM, Georges-Courbot MC, Capron M, Lansoud-Soukate J, Debre P, et al. Defective humoral responses and extensive intravascular apoptosis are associated with fatal outcome in Ebola virus-infected patients. Nat Med (1999) 5(4):423-6. doi:10.1038/7422
11. Gupta M, Greer P, Mahanty S, Shieh WJ, Zaki SR, Ahmed R, et al. CD8-mediated protection against Ebola virus infection is perforin dependent. J Immunol (2005) 174(7):4198-202. doi:10.4049/jimmunol.174.7.4198
12. Ramos-Casals M, Brito-Zeron P, Lopez-Guillermo A, Khamashta MA, Bosch X. Adult haemophagocytic syndrome. Lancet (2014) 383(9927):1503-16. doi:10.1016/S0140-6736(13)61048-X
13. Kortepeter MG, Bausch DG, Bray M. Basic clinical and laboratory features of filoviral hemorrhagic fever. J Infect Dis (2011) 204(Suppl 3):S810-6. doi:10.1093/infdis/jir299
14. Ravelli A, Grom AA, Behrens EM, Cron RQ. Macrophage activation syndrome as part of systemic juvenile idiopathic arthritis: diagnosis, genetics, pathophysiology and treatment. Genes Immun (2012) 13(4):289-98. doi:10.1038/gene.2012.3
15. Tsui WM, Wong KF, Tse CC. Liver changes in reactive haemophagocytic syndrome. Liver (1992) 12(6):363-7. doi:10.1111/j.1600-0676.1992.tb00590.x
16. Bruck N, Suttorp M, Kabus M, Heubner G, Gahr M, Pessler F. Rapid and sustained remission of systemic juvenile idiopathic arthritis-associated macrophage activation syndrome through treatment with anakinra and corticosteroids. J Clin Rheumatol (2011) 17(1):23-7. doi:10.1097/RHU.0b013e318205092d
17. Butin M, Mekki Y, Phan A, Billaud G, Di Filippo S, Javouhey E, et al. Successful immunotherapy in life-threatening parvovirus B19 infection in a child. Pediatr Infect Dis J (2013) 32(7):789-92. doi:10.1097/INF.0b013e31828df4d1
18. Kahn PJ, Cron RQ. Higher-dose Anakinra is effective in a case of medically refractory macrophage activation syndrome. J Rheumatol (2013) 40(5):743-4. doi:10.3899/jrheum.121098
19. Loh NK, Lucas M, Fernandez S, Prentice D. Successful treatment of macrophage activation syndrome complicating adult Still disease with anakinra. Intern Med J (2012) 42(12):1358-62. doi:10.1111/imj.12002
20. Rajasekaran S, Kruse K, Kovey K, Davis AT, Hassan NE, Ndika AN, et al. Therapeutic role of anakinra, an interleukin-1 receptor antagonist, in the management of secondary hemophagocytic lymphohistiocytosis/sepsis/multiple organ dysfunction/macrophage activating syndrome in critically ill children*. Pediatr Crit Care Med (2014) 15(5):401-8. doi:10.1097/PCC.0000000000000078